Name: AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: Administration
Published: 2026-09-17T18:54:38-04:00

Product information and disease description Product description Product information Dosing and administration

Administration

6 evidence topics · 5 sources

Route: intravitreal injection

“Experimental: OTX-TKI (axitinib implant) Drug: OTX-TKI (axitinib implant) Intravitreal Injection of OTX-TKI (axitinib implant)” (opens the source at this quote in a new tab)

Needle gauge and applicator

“Familiar IVT injection with 25g needle” (opens the source at this quote in a new tab)

Administration by a healthcare professional

“Our hydrogel implants and inserts are placed by a healthcare professional and are designed to provide local programmed-release of drug to the ocular surface, intracameral space or intravitreal space.” (opens the source at this quote in a new tab)

Injection site in preclinical studies

“Inferior-temporal injection” (opens the source at this quote in a new tab)

Monitoring the implant after injection

“It has also been observed in the trial that the hydrogels were able to be adequately monitored and that there was limited to no movement of the hydrogel and no migration into the anterior chamber has occurred.” (opens the source at this quote in a new tab)

Visit schedule in the long-term extension

“Subjects are assessed at Week 4, Week 12, and then every 12 weeks thereafter. Additional visits can be conducted with supplemental anti-VEGF injection administered based on investigator discretion.” (opens the source at this quote in a new tab)

Aseptic technique, pre-injection preparation, and post-injection monitoring instructions

No evidence found.